- Innocan Pharma’s (INNO) patent application is pending for a novel cannabis-based anti-itch treatment
- The composition is comprised of a pharmaceutically effective amount of a cannabinoid and active ingredients to aid in the relief of itching
- Innocan Israel and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology using CBD
- Innocan, through its wholly-owned Israeli subsidiary, Innocan Pharma Ltd, is a pharmaceutical tech company
- Innocan Pharma Ltd (INNO) is up 10.81 per cent and is trading at C$0.41 at 11:40 am EST
Innocan Pharma Corporation (INNO) filed for an international patent application for a novel cannabis-based anti-itch treatment.
The composition is comprised of a pharmaceutically effective amount of a cannabinoid and active ingredients to aid in the relief of itching associated with insect bites, rash, cuts, burns or by exposure to various allergens.
“The Pruritus Therapeutics Market is estimated to account for over US$19.10 Billion by 2027 from US$11.77 Billion in 2019, registering a CAGR of approximately 6.2 per cent through the forecast period,” according to a report issued in August 2020 by Reports and Data.
Innocan Pharma believes that its expanding intellectual property portfolio will be a source of potential breakthroughs in skin therapy and further opportunities across a broad spectrum of inflammatory indications which are currently being unmet medically.
Iris Bincovich, CEO, said: “This is another demonstration that Innocan’s science-based approach quickly leads to actionable intellectual property.”
“We plan to launch the Anti-itch Spray in H2 in the EU and the US markets, following a clinical study,” added Bincovich.
Innocan, through its wholly-owned Israeli subsidiary, Innocan Pharma Ltd., is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol.
Innocan Israel and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 Coronavirus using CBD.
Innocan Pharma Ltd. (INNO) is up today with an increase of 10.81 per cent and is trading at C$0.41 at 11:40 am EST.
